Tatva Chintan Pharma Chem Limited — Board Meeting, 02-05-2025: Outcome of Board Meeting

Tatva Chintan Pharma Chem Limited has announced a board meeting on approving the financial results for the quarter and half-year. Consolidated revenue for the year reached ₹715.4 Cr, with a profit after tax of ₹30.35 Cr, showcasing strong performance in specialty chemicals. The Board proposed a final dividend of ₹1 per share (10%) for FY25, subject to shareholder approval. Key audit and internal control roles were assigned to M/s. TNT & Associates (Secretarial Auditor), M/s. Zarna Thakar & Associates (Cost Auditor), and RSM Astute Consultech (Internal Auditor), enhancing governance and compliance.